Management in IG NeuroNet

Coordinator:    Prof. Dr. Erich Wanker
Institution: Max-Delbrück-Centrum für Molekulare Medizin (MDC) Berlin-Buch
Homepage: /
The aim of subproject 9 was the management of the IG NeuroNet. The IG was made up of 11 scientific subprojects with about 35 employees.
The associated technology platform "Interactome" with about 5 colleagues provided comprehensive automated  laboratory technologies for the consortium.
The subprojects that required coordination were active at different locations and in different research areas..
For an efficient central project management of the IG NeuroNet and the technology platform a management office was established at the MDC Berlin in the group of E. Wanker. It was responsible for overseeing the project schedule, reporting, information flow between the subprojects (Fig. 1) and for the organization of all meetings and conferences carried out in the context of NeuroNet. This included planning, implementation and follow-up of the semi-annual project meetings, where the achievements of the IG NeuroNet was presented and the next tasks were discussed and organized.
Furthermore, organization and writing of the annual progress and final reports, coordination of the integration of results in relevant databases, quality management of the investigations, planning and implementation of an IG project website in cooperation with SP8b (external: http://neuronet., internal (password protected):, as well as organization of conferences at the MDC Berlin were among the responsibilities of the management.
On 08./09.10.2010 an international workshop on "protein-protein interactions" ("PPI Berlin - Current Trends in Network Biology") was organized and carried out with great success at the MDC Berlin. About 120 visitors from all over the world, especially from the target group of graduate students and young scientists, convened with renowned experts in network biology to discuss this central subject of the IG NeuroNet.
The common goal of the subprojects of IG NeuroNet was the identification of PPIs, disease pathways and diagnostic markers in order to develop new therapeutic strategies for the future treatment of neurodegenerative diseases.

Figure 1: Organizational chart of IG NeuroNet.
INTRANET (Members login)